Diabetes Care: The effect of stopping continuous blood glucose monitoring on basal insulin therapy in patients with type 2 diabetes

The clinical benefits of real-time continuous blood glucose monitoring (CGM) in patients with type 1 or type 2 diabetes who receive intensive insulin therapy (multiple injections of insulin or insulin pump daily) have been proven, such as reducing glycosylated hemoglobin (HbA1c) and reducing hypoglycemia Incidence rate and so on
.

However, there are few studies on the application of CGM in patients with type 2 diabetes who have not received intensive treatment

Diabetes Hypoglycemia This study aimed to investigate the effect of CGM being discontinued after 8 months of continuous blood glucose monitoring (CGM) in adult patients with type 2 diabetes who were treated with basal insulin instead of bolus insulin

The study was conducted in 15 diabetes centers
in the United States .

The experiment lasted for a total of 14 months, including an 8 -month randomized trial comparing real-time CGM and BGM monitoring, followed by a 6 -month second phase, in which the BGM group continued to use BGM , while the CGM group was randomly reassigned To continue CGM or stop CGM and resume BGM for blood glucose monitoring

The study was conducted in 15 diabetes centers

The results show that in deactivated CGM group, the average range (the TIR) 70-180 mg / dL , starting from CGM before 38% up to CGM.
8 months after 62% , discontinuation CGM reduced to the 14 50% in months .
In the group that continued to use CGM , there was almost no change in TIR from 8 to 14 months .
Comparing the two groups at 14 months, the average TIR difference of the adjusted treatment group was -6% .

Blood glucose results of treatment and control group

Blood glucose results of treatment and control group

24-hour chart of TIR in Phase 2 of each treatment group at baseline, 8th month and 14th month

24-hour chart of TIR in Phase 2 of each treatment group at baseline, 8th month and 14th month

Therefore, it can be seen that in adults with type 2 diabetes who received basal insulin therapy and used real-time CGM for 8 months, stopping CGM reduced the initial gain of TIR by about half, while the latter was achieved during the use of CGM
.

Therefore, it can be seen that in adults with type 2 diabetes who received basal insulin therapy and used real-time CGM for 8 months, stopping CGM reduced the initial gain of TIR by about half, while the latter was achieved during the use of CGM
.

Therefore, it can be seen that in adults with type 2 diabetes who received basal insulin therapy and used real-time CGM for 8 months, stopping CGM reduced the initial gain of TIR by about half, while the latter was achieved during the use of CGM

In summary, the results show that the results show that the results show that type 2 diabetes using basal insulin and other drugs used in combination, the benefits of real-time CGM may last 14 months

DOI: 10.
2337/dc21-1304 leave a message here